Skip to main content

Rensselaer Polytechnic Institute (RPI)

Roy N. Davis

Active Board Member

Active Trustee 2019 - current

Roy N. Davis

Roy N. Davis served as President of Johnson & Johnson Development Corporation and as Corporate Vice President of Business Development for all of Johnson & Johnson (J&J) from January 2008 until his retirement in January 2012. In these roles, he was responsible for helping J&J to determine its new business creation and acquisition strategy and its venture investment portfolio as a global corporation. Mr. Davis was the leader of the J&J wholly owned ventures group as well as the creator of Red Script Ventures, LLC, J&J’s business accelerator.

Roy N. Davis served as President of Johnson & Johnson Development Corporation and as Corporate Vice President of Business Development for all of Johnson & Johnson (J&J) from January 2008 until his retirement in January 2012. In these roles, he was responsible for helping J&J to determine its new business creation and acquisition strategy and its venture investment portfolio as a global corporation. Mr. Davis was the leader of the J&J wholly owned ventures group as well as the creator of Red Script Ventures, LLC, J&J’s business accelerator.

From September 2003 through December 2007, Mr. Davis held the concurrent positions of Company Group Chairman, J&J and Worldwide Franchise Chairman, Diagnostics. He was a member of J&J’s Medical Devices & Diagnostics Group Operating Committee, which oversees one of the world’s largest medical device businesses with over $25 billion in revenue and over 40,000 employees.

Prior to being named Company Group Chairman, Mr. Davis founded Veridex, LLC, a new company within J&J that produced award-winning products for cancer diagnostics. Earlier in his career, Mr. Davis served as Managing Director of J&J Northern Europe and in 1990 was named President of J&J Japan.

Following his retirement, Mr. Davis served as a member of the Innovations Advisory Board for the Cleveland Clinic and the Advisory Board for the Wake Forest Institute for Regenerative Medicine. Mr. Davis has been an advisor to Innosight Consulting since March of 2012 and to its parent company, Huron Consulting, since October 2017. He also is an advisor and Board Member for Clinical Genomics. Mr. Davis received a Bachelor of Science from the State University of New York, and a Master of Science from Rensselaer Polytechnic Institute in 1978.

Roy N. Davis